Home | Welcome to Contract Pharma   
Last Updated Thursday, November 27 2014
Print

Financial Report: Hospira



Published April 30, 2014
Hospira

1Q Revenues: $1.1 billion (+6%)
 
1Q Earnings: $67.9 million (loss of $76.6 million in 1Q13)
 
Comments: Growth in the quarter was driven by Specialty Injectable Pharmaceuticals (SIP), up 10% to $716.3 million, driven mainly by improved pricing and increased volume, as well as competitor supply issues in the U.S. This growth was partially offset by the decline of U.S. sales of oncolytic docetaxel, the device ship-hold effected in February 2013, and foreign currency. Quality and product related charges contributed to losses in 1Q13.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On